Abstracts tagged "Disease Activity"

Abstract Number: 2236 • ACR Convergence 2023
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Jeffrey R Curtis¹, Atul Deodhar², Enrique Soriano³, Emmanouil Rampakakis⁴, May Shawi⁵, Natalie shiff⁶, Marcie Strauss⁷, Chenglong Han⁸, William R Tillett⁹ and Dafna Gladman¹⁰, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷MEDASOURCE, Medical Group, Indianapolis, IN, ⁸Immunology, Janssen Global Services, LLC, Malvern, PA, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Guselkumab (GUS) has demonstrated robust efficacy across key PsA domains at Week (W) 24, with effects sustained or further enhanced through 2 years. Timing…
Abstract Number: 2343 • ACR Convergence 2023
Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications
Eduardo Mantovani Cardoso¹, Rachel Simon¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by multi-systemic involvement and difficult-to-predict disease flares. Hydroxychloroquine (HCQ) has long been recognized as…
Abstract Number: 0333 • ACR Convergence 2023
Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Heather Lapidus Glassner and Elizabeth Luce, MyHealthTeam, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) leads to symptoms of pain, stiffness, swelling, and fatigue. Patients often report periods of increased symptoms (flares) followed by remission.The purpose…
Abstract Number: 0505 • ACR Convergence 2023
Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study
Shashank Cheemalavagu¹, Yuxuan Jin² and M. Elaine Husni³, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Achieving minimal disease activity (MDA) is an important treatment goal in psoriatic arthritis (PsA), as it leads to improved clinical outcomes and quality of…
Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Anirudh Subramanian Muralikrishnan¹, Barbara Dreo², Angelika Lackner¹, Rusmir Husic³, Florentine Moazedi-Fuerst³, Josef Hermann⁴, Philipp Bosch¹, Johannes Fessler¹, Jens Thiel⁵ and Martin Stradner¹, ¹Medical University of Graz, Graz, Austria, ²Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Meduni Graz, Graz, Austria, ⁴Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…
Abstract Number: 1045 • ACR Convergence 2023
Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis
Tadashi Okano¹, Kenji Mamoto¹, Yutaro Yamada¹, Shohei Anno², Asami Yagami¹, Yuka Domae¹, Shingo Washida¹, Yuko Yoshida¹, Tatsuya Koike³ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: In recent years, the concept of D2T RA (difficult-to-treat rheumatoid arthritis) has become widespread, and D2T RA patients are defined as a state in…
Abstract Number: 1313 • ACR Convergence 2023
Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis
Brian Andonian, Leanna Ross, Alyssa Sudnick, Johanna Johnson, Carl Pieper, Connie Bales, Kathryn Porter Starr, William Kraus and Kim Huffman, Duke University, Durham, NC
Background/Purpose: Older persons with rheumatoid arthritis (RA) are at increased risk for sarcopenic obesity, physical disability, adverse drug events, and cardiovascular disease; thus, there is…
Abstract Number: 1437 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
William R Tillett¹, Joseph Merola², Yoshiya Tanaka³, Ennio G Favalli⁴, Dennis McGonagle⁵, Jessica A Walsh⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Vanessa Taieb⁹ and Christopher T Ritchlin¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, ⁶Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Colombes, France, ¹⁰University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Given the chronic nature of PsA, sustaining high levels of disease control with treatment is important. Assessing maintenance of response in patients (pts) that…
Abstract Number: 1896 • ACR Convergence 2023
Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Pamela Gonzalez Manrique¹, Vinit Gilvaz², Ravinder Kaler³, Neha Batra³ and Anthony Reginato², ¹Roger Williams Medical Center, North Providence, RI, ²The Warren Alpert Medical School of Brown University, Providence, RI, ³Roger Williams Medical Center, Providence, RI
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…
Abstract Number: 2239 • ACR Convergence 2023
Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
Arthur Kavanaugh¹, Kristi Mizelle², Oliver FitzGerald³, Enrique Soriano⁴, Peter Nash⁵, Sandra Ciecinski⁶, Limei Zhou⁶, Arathi Setty⁶ and Laure Gossec⁷, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Tidewater Physicians Multispecialty Group, Newport News, VA, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Brisbane, Australia, ⁶AbbVie, Inc., North Chicago, IL, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: A main goal of therapy for patients (pts) with PsA is to achieve and maintain the lowest possible level of disease activity across domains.1…
Abstract Number: 2365 • ACR Convergence 2023
Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression
Vasuki Ranjani Chellamuthu¹, Maria Noviani², Ahmad bin Mohamed Lajam¹, Andrea Hsiu Ling Low² and Salvatore Albani¹, ¹Translational Immunology Institute, SingHealth, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc) is a heterogenous autoimmune disease characterized by fibrosis, vascular abnormalities and immune dysregulation. Characterization of peripheral blood immune signatures in relation…
Abstract Number: 0336 • ACR Convergence 2023
Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists
victoria werth¹, Annegret Kuhn², Joseph F. Merola³, Joerg Wenzel⁴, Cristina Vazquez-Mateo⁵, Sanjeev Roy⁶, Erik Thomas⁵, Oliver Guenther⁷, Ying Sun⁷, Alexandra Lauer⁷, Almary Guerra Rodriguez⁸, Patricia Koochaki⁹ and Paul Kamudoni⁷, ¹University of Pennsylvania, Wynnewood, PA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, and University of Münster, Münster, Germany, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴University Hospital of Bonn, Bonn, Germany, ⁵EMD Serono, Billerica, MA, ⁶Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, ⁷the healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Laife Reply GmbH, Frankfurt am Main, Germany, ⁹ICON Clinical Research LLC, Raleigh, NC
Background/Purpose: Greater understanding of cutaneous signs and symptoms is needed to comprehensively define and measure cutaneous disease activity in lupus erythematosus. Herein, we interviewed dermatologic…
Abstract Number: 0516 • ACR Convergence 2023
Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry
Casper Webers¹, Rabab Nezam El-Din¹, Marin Been¹, Harald Vonkeman² and Astrid van Tubergen¹, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ²Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands
Background/Purpose: In the management of axial spondyloarthritis (axSpA), treatment intensification (TI) is recommended in patients with high disease activity (HDA). However, in practice, in most…
Abstract Number: 0807 • ACR Convergence 2023
Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records
David Cheng¹, Dana Weisenfeld², Kumar Dahal², Qing Liu², Vidul Ayakulangara Panickan³, Mary Jeffway², Thany Seyok², Gregory McDermott², Michael Weinblatt⁴, Nancy Shadick⁵, Tianxi Cai⁶ and Katherine Liao², ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Real-world data including electronic health records (EHRs) are a promising resource for learning to optimize treatment strategies for rheumatoid arthritis (RA). A major challenge…
Abstract Number: 1047 • ACR Convergence 2023
Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints
Maria I. ("Maio") Danila¹, Giovanna Rosas², Fenglong Xie², Jeffrey R Curtis³, Kiara Aaron², Stephanie Ford² and Laura Hughes⁴, ¹University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham; East Alabama Medical Center, Birmingham, AL
Background/Purpose: Infrared thermography (IRT) is an emerging technology that has the potential to rapidly assist in identifying joint inflammation in patients with joint symptoms. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.